Most traditional health insurance policies classify obesity medications as elective treatments rather than medical necessities
If any patient is concerned about their treatment, they should discuss this with their clinician. In March this year, NICE recommended a weekly injection of semaglutide, manufactured by Novo Nordisk under the brand name Wegovy, for adults who have at least one weight-related comorbidity and a body mass index (BMI) of at least 35kg/m2
(285), utilizing UK Biobank data from 33,441 individuals with hyperglycemia (including 7,969 with T2DM) over a median 12.3-year prospective follow-up, found that the highest compared with the lowest Alternate Mediterranean Diet (AMED) score was associated with a 21% reduction in DKD risk (HR = 0.79, 95% CI: 0.670.94)
While oral supplements are convenient, the first-pass metabolism in the digestive tract can break down the molecule before it reaches the bloodstream